Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX
Cumberland Pharmaceuticals — Investor Presentation (2021)
23 slides from Cumberland Pharmaceuticals's investor presentation, 2021
Slide 1: Corporate Presentation
Corporate Presentation Nasdaq CPIX
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements Important factors that could cause actual results to differ concerning our approved products and product materially from those indicated by such forward-looking development, our technology, our competitors, our statements in
Slide 3: Company Overview
Company Overview • Specialty pharmaceutical company • Portfolio of seven FDA approved products • Promoted by two national sales forces • Several near-term catalysts for new growth opportunities • Vibativ post-acquisition integration and market expansion • Next Generation Caldolor product launch • Re
Slide 4: Mission & Strategy
Mission & Strategy Mission: Advance Patient Care through delivery of high quality medicines Strategy: Build a portfolio of Specialized biopharmaceutical brands 4
Slide 5: Product Portfolio
Product Portfolio Product Development: Product Acquisition: 5
Slide 6: Acetadote: IV treatment for acetaminophen overdose
• IV treatment for America’s leading cause of poisoning • Treats liver toxicity associated with acetaminophen overdose • Developed and registered by Cumberland • Acetadote now standard of care • Cumberland developed unique EDTA free formulation • Maintaining significant market share *National Poison
Slide 7: Caldolor: injectable ibuprofen
• Injectable delivery of ibuprofen • Developed and registered by Cumberland • Antipyretic, analgesic & anti-inflammatory properties • Evaluated in published studies with ~ 2,000 patients • Over 2.3 million doses administered • Pediatric labeling approved by FDA • Study in newborns recently completed
Slide 8: Next Generation Caldolor ready-to-administer bag
• New, ready to administer without further dilution • Designed to help address National Opioid Crisis • First and only FDA-approved pre-mixed bag of ibuprofen • Completed a soft-launch • National launch underway, gaining early acceptance and growing demand • Aim to significantly grow Caldolor’s sale
Slide 9: Kristalose: crystalline lactulose
• Unique crystalline formulation of lactulose • Prescription strength laxative • Clinically proven increases in patient satisfaction • Repositioned to reflect branded status • New pricing allowed co-pay support and improved Managed Care coverage 9
Slide 10: Commercial Portfolio Expansion Strategy
Commercial Portfolio Expansion Strategy IDENTIFY ACQUIRE Late Stage Candidates Under-Promoted, PRODUCT Approved Brands PORTFOLIO EXPAND DEVELOP Existing Products Early-Stage Candidates 10
Slide 11: Acquisition Initiative
Acquisition Initiative Active, ongoing initiative to identify, evaluate and acquire/license new products into the portfolio Source opportunities through direct efforts and intermediaries GOAL TO ADD ONE NEW Seek commercial and late stage development PRODUCT PER YEAR assets that fit our strategy and f
Slide 12: Vibativ: injectable antibiotic
• Acquired following development by Astellas & Theravance • Injectable antibiotic that treat serious, life-threatening infections • Hospital product that aligns well with our current infrastructure • New data demonstrates superiority over vancomycin in select patients with bacterial pneumonia. * Pub
Slide 13: RediTrex: injectable methotrexate
• New injectable delivery of methotrexate • Designed for the treatment of arthritis and psoriasis • Widely used throughout Europe with a strong brand presence • The U.S. methotrexate market is demonstrating significant growth • FDA-approved and currently implementing soft launch • Full launch planne
Slide 14: Ifetroban Overview
Ifetroban Overview • Cumberland’s first new chemical entity (NCE) • A potent, selective antagonist of thromboxane receptor (TPr) • Initially developed by Bristol-Myers Squibb as an anti-platelet agent • Safety is well-established in 26 clinical studies with over 1,300 subjects • Collaborating with V
Slide 15: Ifetroban Development Pipeline
Ifetroban Development Pipeline Preclinical IND Phase I Phase II Phase III NDA Boxaban® (aspirin-exacerbated respiratory disease) Vasculan ® (systemic sclerosis) Dyscorban™ (Duchenne muscular dystrophy)
Slide 16: Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) A rare, fatal, genetic neuromuscular disease characterized by the progressive loss of muscle which results in deterioration of the skeleton, heart and lungs Cumberland is investigating ifetroban for the treatment of cardiomyopathy associated with DMD New data
Slide 17: Slide 17
Slide 18: Academic research collaborators
University of Tennessee University of Tennessee Knoxville, TN Health Science Center Memphis, TN Vanderbilt University University of Mississippi Nashville, TN Oxford / Jackson, MS Louisiana State University Medical University of Health Sciences South Carolina New Orleans, LA Charleston, SC 18
Slide 19: Expanding Our Product Portfolio
Expanding Our Product Portfolio Ifetroban Next Gen In-Line Brands Deploying a Multifaceted Strategy to Create Value 19
Slide 20: Financial Overview
Financial Overview ($ in millions) 2020 Net Revenues $37.4 Cost of Products Sold (8.7) Gross Profit $28.8 Selling & Marketing (14.8) Research & Development (5.8) General Administrative (10.2) Amortization & Other (4.4) Discontinued Operations Income 3.2 Net Income (loss) (3.3) Cash Flow from Operati
Slide 21: Balance Sheet Summary
Summary Balance Sheet ($ IN MILLIONS) As of Dec. 31, 2020 CASH & EQUIVALENTS $24.8 TOTAL ASSETS 96.5 T O TA L L I A B I L I T I E S 49.5 T O TA L E Q U I T Y 47.0 *$15 million available on revolving line of credit *Tax carry forward credits of $44 million available *Continued Share Repurchase Progra
Slide 22: Cumberland Moving Forward
Cumberland Moving Forward Diverse product portfolio with 7 FDA approved brands Proven development and commercialization capabilities Various initiatives in place to support near-term growth Phase II products in development with upcoming study milestones Valuation gap given assets, cash, sales, and p
Slide 23: Nasdaq CPIX
as a CUMBERLAND 8 J Via ee ee, Oe Nasdaq CPIX
Cumberland Pharmaceuticals — Investor Presentation (2021) on 6ix